By Rory McCann, Marketing Manager & Conference Producer, LSN
Eran is very active in the world of early-stage startups and fundraising within life science and is a recent contributor to the Redefining Early Stage Investments (RESI) community. Eran speaks with us about the value he’s found at RESI and how his many roles helped him make the most of his experience and add value to others.
Digital RESI takes place June 8-10. There’s still time to save on early bird rates, sign up by May 7 to save!
By Ashley Zborowski, Director of Business Development, LSN
The Redefining Early Stage Investment (RESI) Service Provider Showcase helps companies gain unprecedented visibility into the early-stage life science community and leverages Life Science Nation (LSN)’s close-knit network of key decision-makers to make promising connections with future clients. Service providers are an important asset in the fundraising ecosystem, and this new program is designed to increase their exposure to the RESI community.
Digital RESI, June 8-10, proudly features service providers advancing early-stage startups within drugs, devices, diagnostics, and digital health. Often the unsung heroes of fundraising startups, these powerful partnerships are essential in commercializing, building teams, conducting research, manufacturing, and so much more! Meet and get to know some featured service providers at Digital RESI June, and contact us to learn more about this special offer.
MERIT is an innovative specialty CRO providing clinical trial data collection and interpretation in the ophthalmology and respiratory disciplines. Our portfolio of solutions offers deep clinical expertise, unique technology, and exceptional service for our partners, sponsors, and CROs.
At PharmaDirections, gain access to top talent without the cost or risk of a full-time, in-house team. More than just a consultant or outside vendor, we are an extension of your team and are accountable for all aspects of a project, from discovery to regulatory approval.
SPH Phililab an innovation pharmaceutical company that develop, registrar, and manufacture generic and modified new drug product in USA and China. Our product portfolio focuses on the two largest pharmaceutical markets in the world, plus our unique background of management team and scientists made us a pioneer as an international player in the pharmaceutical industry.
An early-stage healthcare venture fund with teams based in USA and Asia looks to invest in visionary teams and cutting-edge technologies in both life science and digital health solutions.
The firm’s philosophy is not to take a one-size-fits-all approach to investing. The firm draws from their domain expertise and diversified experiences across the full healthcare spectrum to cover both Biopharma and Digital Health sectors. The firm’s aim is to support companies that can achieve differentiated therapeutic results through truly novel approaches. Combining scientific rigor and strategic connections within our network, the firm provides guidance and add value to our portfolio companies as they grow. The firm is seeking to work with companies from late Seed to Series B, and is open to global opportunities.
The firm is focused on two main investment themes:
(1) Life Sciences – the firm looks for sound scientific principles and seek innovative approaches, including breakthrough medicines and platform technologies. The firm’s key areas of interest include neurological diseases, metabolic diseases, and infectious diseases. The firm’s investment team engages with entrepreneurs and companies from early pre-clinical development where there is compelling science with cell and/or animal model proof of concept data and invests through pre-clinical and early clinical proof of concept stages;
(2) Digital Health / Bio IT
Digital health is a transformational area in healthcare. The firm looks for technology platforms that enable pertinent scientific insights into drug development and design or enhanced delivery of care from providers to patients. Key areas of interest include synthetic biology, machine learning for drug discovery (proteomics and metabolomics), and tools that help reduce healthcare costs.
The firm is looking for experienced management teams with strong scientific expertise and management skills.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A publicly traded company focused on oncology therapeutics is seeking therapeutic opportunities in the oncology space. The firm is looking to partner and collaborate as well as in-license, but is primarily seeking partnerships. The firm seeks assets that have at the very least cellular proof of concept, but prefers companies to have some animal data or are approaching pre-IND studies. The firm is also willing to partner with unique and differentiated drug discovery platform companies. The firm will partner globally, but primarily partners with US and Europe-based companies.
The firm is interested only in oncology and immuno-oncology assets in high unmet tumor indications including RCC and HCC. For modality, the firm is interested only in small molecule and biologics. The firm is willing to consider therapeutics targeting both solid and liquid tumors. The firm will also partner with drug discovery companies, such as those using AI-based technologies to identify new therapeutic biology, as well as platform companies.
The firm will only partner with companies that have a strong IP position and a clear differentiating discovery and development strategy. The firm looks for startups with unique “First-in-Class” therapeutics and platforms.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A private investment firm based in USA and Asia with limited partners including institutional investors from US and China, typically invests $5-10M in businesses from Series A to pre-IPO and public traded companies. The firm is open to leading or following a syndicated round. The firm is now seeking opportunities in North America.
The firm invests across therapeutics, medical devices, diagnostics, platform technologies, and healthcare IT and is looking for companies that are top 3 in their niche sector. Within therapeutics, the firm prefer clinical stage projects. The firm is opportunistic in terms of disease areas including orphan indications. Within device and diagnostics, the firm prefers post-prototype products with clinical validation.
The firm may request board representation or board observer ship on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
A healthcare-focused venture capital and growth equity firm provides $15-$40 million of equity capital per company over the life of the investment. With offices in USA and Europe, the firm is primarily looking for companies throughout North America and Europe.
The firm is currently interested in companies in areas of medical technology, biopharmaceuticals, diagnostics, medical devices, digital health, and veterinary medicine. Significant emphasis is placed on the clinical utility and health economics of potential investments. The firm focuses on later-stage opportunities that are already commercialized or are close to commercialization. The firm is generally open in terms of indications.
The firm looks for management teams that are very willing to work alongside them, and the firm most always looks to take a board seat. The firm is open to investing in both public and privately held companies, is open to a variety of deal structures, and can consider equity investments or buy-out opportunities.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
The firm is the venture arm of the world’s leading provider of products and services for people with chronic kidney failure. The Corporate VC has offices in USA, Germany, and Israel, and is actively seeking early-stage investment opportunities that align with the parent company’s core businesses. Typical size of investment is around $5M, and the firm focuses on Series A to B rounds. The fund is open to global opportunities.
The Corporate VC is interested in products and technologies across therapeutics, medical devices, diagnostics, and digital health that target the following therapeutic sectors: chronic kidney disease and dialysis, intensive care medicine, cardiovascular diseases, autoimmune diseases, diabetes, and other kidney-related diseases. In terms of medical devices, the firm is open to 510k and PMA regulatory pathways.
The Corporate VC is open to working with all types of management teams. The firm can act as either lead or co-investor.
If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.
Next Phase Newsletter 